PHS
AUTL

PFM Health Sciences’s Autolus Therapeutics AUTL Stock Holding History

PFM Health Sciences’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-219,628
Closed -$6.74M – 98
2018
Q3 		$6.74M Buy
219,628
+21,754
+11% +$587K 0.1% 108
2018
Q2 		$5.3M Buy
+197,874
New +$5.23M 0.08% 108

Other funds holding AUTL

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

PFM Health Sciences's AUTL Position: Q4 2018 in Review

PFM Health Sciences sold out of Autolus Therapeutics (AUTL) in Q4 2018, closing a stake of 219,628 shares — an estimated $6.74M sold.

PFM Health Sciences first reported a position in AUTL in Q2 2018 and held it in 2 quarters. The position peaked at $6.74M in Q3 2018. 38 funds tracked by Wall St. Rank hold AUTL as of Q4 2018.

  • PFM Health Sciences reported no remaining Autolus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • PFM Health Sciences sold 219,628 Autolus Therapeutics shares in Q4 2018, an estimated $6.74M.
  • PFM Health Sciences first reported a position in Autolus Therapeutics in Q2 2018 and held it in 2 quarters.
  • PFM Health Sciences's Autolus Therapeutics position peaked at $6.74M in Q3 2018.
  • 38 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2018.

Based on PFM Health Sciences's 13F filing for Q4 2018, filed 14 Feb 2019.